Hypha are excited to announce they have relocated from Slough to Milton Park in Oxfordshire, one of the largest science… read more →

Metabolites derived from any human flavin-containing monooxygenase (FMO) subtype can now be produced as a service offering at Hypha. Recombinant… read more →

Great to see Hypha recognised for producing a glucuronide metabolite of praliciguat (M3) in the paper just out in the… read more →

We illustrate application of our one-stop metabolite shop in meeting metabolite requirements for various client projects using different techniques in… read more →

Hypha remain fully operational and are monitoring the COVID-19 situation closely. We have implemented a number of measures in response… read more →

Some metabolites are not easy to access. Even if sufficient material can be isolated from biological matrices for definitive metID,… read more →

As a leading specialist CRO for drug metabolite provision, Hypha has formed a partnership with Cypex Limited, experts in the… read more →

Our latest PolyCYPs bulletin features a case study in which one of our US pharma clients needed rapid access to… read more →

We are excited to announce the official launch of our One-Stop Metabolite Shop, which offers a complete solution for pharma… read more →

WEBINARS – 5th & 10th December If you missed the recent webinars on Hypha’s new “One-stop metabolite shop” featuring our… read more →